ClinicalTrials.gg
Drug

Pafolacianine clinical trials

Also written OTL38 and Cytalux.

studies test it
12
open now
5
in phase 3
1
first study started
2014

How each study uses Pafolacianine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Pafolacianine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Nov 2021 · CYTALUX · NDA 214907 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

OTL38 for Injection
2
CYTALUX™ (pafolacianine) injection
2
pafolacianine injection
2

Brand

Cytalux
2

Development codes

OTL38
6

Studies by the year they started

12 studies that test it; most in 2015 (3)

Studies that test Pafolacianine, by start year
YearStudies
20141
20153
20171
20221
20242
20253
20261

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
4
Phase 3
1
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 9

On Target Laboratories, LLC (3) · University of Pennsylvania (2) · Indiana University (1) · Chandru Sundaram (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Cedars-Sinai Medical Center (1) · Mayo Clinic (1) · John Waters (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 1 in phase 3

Studies that test Pafolacianine, phase 3 first.

Studies

Open first, then newest update. How each study uses Pafolacianine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 12

Given beside what is tested · 2 — Pafolacianine is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Pafolacianine

Codes

What other systems call Pafolacianine · ClinicalTrials.gg INT001744

  • MeSH (NLM) C000720187PafolacianineConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) F7BD3Z4X8LPAFOLACIANINEConfirmed FDA, NLM, Wikidata
  • RxNorm 2586857One source FDA
  • Wikidata Q27277759pafolacianineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C175834PafolacianineOne source FDA
  • DrugBank DB15413One source Wikidata

Also registered as pafolacianine sodium (UNII 4HUF3V875C · RxNorm 2586858).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.